G. Oikonomopoulos

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping

Joseph Sgouros, Alexia Eliades, Kyriaki Papadopoulou, Nikolaos Korfiatis et autres

Background Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-challenge …

gr, cy (code pays fourni par la source)

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer

Elena Fountzilas, John Souglakos, John Alafis, Katerina Dadouli et autres

Background: The superiority of paclitaxel/ramucirumab over alternative therapeutic regimens in patients with gastric cancer has yet to be defined. Our aim was to evaluate whether second-line treatment with paclitaxel/ramucirumab is superior compared with other therapies. Patients and methods: Retrospective real-world data from …

cy, gr (code pays fourni par la source)

87P Real-world evidence of FTD/TPI and bevacizumab combination therapy in metastatic colorectal cancer: Survival and clinicopathological insights

A. Koumarianou, Anastasios Ntavatzikos, David G. Symeonidis, K. Kamboli et autres

gr (code pays fourni par la source)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Foteinos-Ioannis D. Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, Thomas Papastergiou et autres

Background: Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in …

gr, de, gb (code pays fourni par la source)

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

Giannis Mountzios, Epaminontas Samantas, Karsten Senghas, Eleftherios Zervas et autres

BACKGROUND: The advanced lung cancer inflammation index [ALI: body mass index × serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is easily reproducible. We hypothesized that ALI could assist guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICIs). …

gr, de (code pays fourni par la source)

SO-2 Prevalence and prognostic role of inherited germline mutations in cancer predisposing genes in unselected patients with pancreatic cancer

Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos et autres

gr, cy (code pays fourni par la source)

Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer

Periklis G. Foukas, Georgia-Angeliki Koliou, Alexandra Papoudou‐Bai, Antonia V. Charchanti et autres

gr (code pays fourni par la source)

Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer

George E. Pentheroudakis, Vassiliki Kotoula, Georgia-Angeliki Koliou, Kyriaki Papadopoulou et autres

gr (code pays fourni par la source)

Left Ventricular Pacing through Coronary Sinus Is Feasible and Safe for Patients with Prior Tricuspid Valve Intervention

Skevos K. Sideris, Maria I. Drakopoulou, G. Oikonomopoulos, Konstantinos A. Gatzoulis et autres

BACKGROUND: In the presence of tricuspid valve intervention, right ventricular lead implantation is associated with the potential risk of tricuspid valve malfunction leading to a tricuspid regurgitation. Few cases have been reported with successful left ventricular pacing via the coronary sinus (CS) …

gr (code pays fourni par la source)

P-143 Weight Loss during chemotherapy in patients with advanced Oesophagogastric (OG) and Hepatobiliary-Pancreatic (HPB) cancers is not a surrogate for disease progression

G. Oikonomopoulos, Susan M. C. Payne, S. Ngan, S. Chosdhury et autres

gb (code pays fourni par la source)

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

Kostas Syrigos, Muhammad Wasif Saif, Eleni M. Karapanagiotou, G. Oikonomopoulos et autres

As a result of improved effectiveness of first-, second-line and maintenance therapeutic regimens in non-small cell lung cancer, there is need for new options as third-line treatment. Erlotinib and gefitinib are currently the only drugs of proven efficacy in the third-line setting. …

gr, it (code pays fourni par la source)